The study will be carried out in partnership with The GOG Foundation and the European Network of Gynaecological Oncological ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Among these developments is trastuzumab deruxtecan (brand name: Enhertu), which offers new hope specifically for patients who harbor HER2 mutations in their lung cancer, a type once challenging to ...

--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) in combination with ...

Confirmed objective response rate (ORR) with ENHERTU plus pertuzumab was ... the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new ...

The first patient has been dosed in the DESTINYEndometrial01 phase 3 trial evaluating Enhertu (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

Confirmed objective response rate (ORR) with ENHERTU plus pertuzumab was 85.1% versus 78. ... the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to ...